Abstract
Aim: to investigate the influence of Bosentan on serum cytokines levels in pts with idiopathic pulmonary arterial hypertension (IPAH).
Methods: In the single-center comparative study we included 35 pts aged 35,2±9,6ys with IPAH confirmed by RHC (WHO Functional Class (FC) II-IV) without systemic inflammation signs. On top of stable therapy for at least 3 months Bosentan therapy was started 62,5 mg twice daily for 4 wks. At wk4 the patients were randomized 1:1 by the envelope method to have bosentan 125 or 250 mg/day. At baseline, at wk3 and wk12 visits the pts underwent the clinical and lab assessment (FC, 6-minute walking test (6-MWT), Echo, RHC,routine lab+ measurement of high sensitivity C-reactive protein (hsCRP) and serum pro-inflammatory serum cytokines (interleukin (IL) 1β, 8, TNFa).
Results: At baseline 2 groups did not differ in age, disease duration, functional, and hemodynamic parameters, hsCRP levels were normal in both groups.
Conclusion: The influence of Bosentan 125 and 250 mg/day on some cytokines levels to wk12 showed its anti-inflammatory effect in IPAH pts.
- © 2012 ERS
